Tango Therapeutics, Inc.
TNGX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $42,069 | $36,527 | $24,860 | $37,042 |
| % Growth | 15.2% | 46.9% | -32.9% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $42,069 | $36,527 | $24,860 | $37,042 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $143,918 | $115,198 | $105,906 | $77,636 |
| G&A Expenses | $43,746 | $35,502 | $30,025 | $17,596 |
| SG&A Expenses | $43,746 | $35,502 | $30,025 | $17,596 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $187,664 | $150,700 | $135,931 | $95,232 |
| Operating Income | -$145,595 | -$114,173 | -$111,071 | -$58,190 |
| % Margin | -346.1% | -312.6% | -446.8% | -157.1% |
| Other Income/Exp. Net | $15,501 | $12,563 | $2,949 | $247 |
| Pre-Tax Income | -$130,094 | -$101,610 | -$108,122 | -$57,943 |
| Tax Expense | $208 | $134 | $54 | $292 |
| Net Income | -$130,302 | -$101,744 | -$108,176 | -$58,235 |
| % Margin | -309.7% | -278.5% | -435.1% | -157.2% |
| EPS | -1.19 | -1.08 | -1.23 | -0.94 |
| % Growth | -10.2% | 12.2% | -30.9% | – |
| EPS Diluted | -1.19 | -1.08 | -1.23 | -0.94 |
| Weighted Avg Shares Out | 109,227 | 94,572 | 87,820 | 62,108 |
| Weighted Avg Shares Out Dil | 109,227 | 94,572 | 87,820 | 62,108 |
| Supplemental Information | – | – | – | – |
| Interest Income | $7,890 | $6,619 | $1,456 | $495 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $2,499 | $2,415 | $1,608 | $897 |
| EBITDA | -$143,096 | -$111,758 | -$109,463 | -$57,293 |
| % Margin | -340.1% | -306% | -440.3% | -154.7% |